

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM631929

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Horizon Orphan LLC		03/15/2021	Limited Liability Company: DELAWARE
Horizon Therapeutics USA, Inc.		03/15/2021	Corporation: DELAWARE
Viela Bio, Inc.		03/15/2021	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Citibank, N.A.		
Street Address:	388 Greenwich Street		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10013		
Entity Type:	Association: UNITED STATES		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Serial Number:	90497655		
Serial Number:	90304262	K KRYSTEXXA PEGLOTICASE	
Serial Number:	88420346	VIELABIO	
Serial Number:	88420342	VIELABIO	
Serial Number:	88045691	UPLIZNA	
Serial Number:	88149113	VIELABIO	
Serial Number:	88149112	VIELABIO	
CORRESPONDENCE DATA			
Fax Number:	8009144240		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	800-713-0755		
Email:	Michael.Violet@wolterskluwer.com, ECarrera@cahill.com		
Correspondent Name:	CT Corporation		
Address Line 1:	4400 Easton Commons Way		
Address Line 2:	Suite 125		
Address Line 4:	Columbus, OHIO 43219		

OP \$190.00 90497655

TRADEMARK

NAME OF SUBMITTER:	Elaine Carrera
SIGNATURE:	/Elaine Carrera/
DATE SIGNED:	03/15/2021
Total Attachments: 6 source=25. Trademark Security Agreement#page1.tif source=25. Trademark Security Agreement#page2.tif source=25. Trademark Security Agreement#page3.tif source=25. Trademark Security Agreement#page4.tif source=25. Trademark Security Agreement#page5.tif source=25. Trademark Security Agreement#page6.tif	

TRADEMARK SECURITY AGREEMENT

THIS TRADEMARK SECURITY AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Trademark Security Agreement”) is made effective as of March 15, 2021, by and from HORIZON ORPHAN LLC, a Delaware limited liability company, HORIZON THERAPEUTICS USA, INC., a Delaware corporation and VIELA BIO, INC., a Delaware corporation (each a “Grantor” and collectively, the “Grantors”), to and in favor of CITIBANK, N.A., as Administrative Agent and Collateral Agent (as defined in the Credit Agreement referenced below) for the Secured Parties (as defined in the Credit Agreement referenced below) (in such capacities, the “Grantee”).

WHEREAS, Horizon Therapeutics USA, Inc., a Delaware corporation, as borrower, the other Loan Parties (as defined in the Credit Agreement referenced below) from time to time party thereto, the Lenders (as defined in the Credit Agreement referenced below) from time to time party thereto and Grantee, have entered into a Credit Agreement dated as of May 7, 2015 (as amended by Amendment No. 1, dated as of October 25, 2016, as further amended by Amendment No. 2, dated as of March 29, 2017, as further amended by Amendment No. 3, dated as of October 23, 2017, as further amended by Amendment No. 4, dated as of October 19, 2018, as further amended by Amendment No. 5, dated as of March 11, 2019, as further amended by Amendment No. 6, dated as of May 22, 2019, as further amended by Amendment No. 7, dated as of December 18, 2019, as further amended by the Incremental Amendment and Lender Joinder Agreement, dated as of August 17, 2020, and as further amended, restated, modified and supplemented prior to the date hereof, the “Credit Agreement”).

WHEREAS, as of the date hereof, the Grantors are party to the Credit Agreement, as Guarantors.

WHEREAS, the Grantors have entered into a U.S. Pledge and Security Agreement dated as of May 7, 2015 (as may be amended, restated, supplemented or otherwise modified from time to time, the “U.S. Security Agreement”).

WHEREAS, each Grantor owns the trademarks listed opposite such Grantor’s name on Schedule A attached hereto (the “Trademarks”), which Trademarks are pending or registered with the United States Patent and Trademark Office.

WHEREAS, this Trademark Security Agreement has been executed in conjunction with the security interest granted under the U.S. Security Agreement to the Grantee for the benefit of the Secured Parties. In the event that any provisions of this Trademark Security Agreement are deemed to conflict with the U.S. Security Agreement, the provisions of the U.S. Security Agreement shall govern.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed that:

- 1) Definitions. All capitalized terms not defined herein shall have the respective meaning given to them in the Credit Agreement or the U.S. Security Agreement.
- 2) The Security Interest.

(a) This Trademark Security Agreement is made to secure the prompt and complete payment and performance of all the Secured Obligations. Upon the occurrence of the Termination Date, the Grantee shall promptly, upon such satisfaction, execute, acknowledge, and deliver to the applicable Grantor all reasonably requested instruments in writing releasing the security interest in the Trademarks acquired under the U.S. Security Agreement and this Trademark Security Agreement.

(b) Each Grantor hereby pledges and grants to the Grantee, on behalf of and for the benefit of the Secured Parties, a security interest in all of such Grantor's right, title and interest, wherever located and whether now owned or hereafter acquired, in and to (i) any and all trademarks and trademark applications, including those listed on Schedule A hereto; (ii) all inventions and improvements described and claimed therein; (iii) all reissues, divisions, continuations, renewals, extensions, and continuations-in-part thereof; (iv) all income, royalties, damages, claims, and payments now or hereafter due or payable under and with respect thereto, including, without limitation, damages and payments for past and future infringements thereof; (v) all rights to sue for past, present, and future infringements thereof; and (vi) all rights corresponding to any of the foregoing throughout the world.


3) Governing Law. **THIS TRADEMARK SECURITY AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.**

4) Recordation. The Grantors hereby authorize and request that the Commissioner of Patents and Trademarks record this Trademark Security Agreement.


5) Notwithstanding anything to the contrary set forth herein, this Trademark Security Agreement, the liens created hereby and the rights and remedies of the Grantee hereunder are subject to the terms and provisions of each Intercreditor Agreement (if any). In the event of any inconsistency between the provisions of this Trademark Security Agreement and any Intercreditor Agreement, the provisions of such Intercreditor Agreement shall supersede the provisions of this Trademark Security Agreement. If any Grantor shall pledge any assets or undertake any actions to perfect or protect any lien on any assets pledged in connection with the Collateral Documents or this Trademark Security Agreement, such Grantor may simultaneously pledge such assets or undertake such actions with respect to such assets as necessary to comply with the provisions set forth in any Intercreditor Agreement, without further request or consent by the Secured Parties. Any provision of this Trademark Security Agreement to the contrary notwithstanding, the Grantors shall not be required to act or refrain from acting in a manner that is inconsistent with the terms and provisions of any Intercreditor Agreement.

IN WITNESS WHEREOF, the Grantors have executed this Trademark Security Agreement effective as of the date first written above.


**HORIZON ORPHAN LLC
HORIZON THERAPEUTICS USA, INC.**

By: 
Name: Paul W. Hoelscher
Title: Chief Financial Officer

VIOLA BIO, INC.

By: 
Name: Paul W. Hoelscher
Title: Treasurer

CITIBANK, N.A.,
as Administrative Agent and Collateral Agent

By: 

Name: Michael Tortora

Title: Managing Director & Vice President

Trademarks and Applications

	Owner	Trademark	Appl. No. Filing Date	Reg. No. Reg. Date	Status
1.	Horizon Orphan LLC	DESIGN ONLY	90497655 01/29/2021	N/A	Pending
2.	Horizon Therapeutics USA, Inc.	K KRYSTEXXA PEGLOTICASE	90304262 11/06/2020	N/A	Pending
3.	Viela Bio, Inc.	VIELABIO	88420346 05/08/2019	6206620 11/24/2020	Registered
4.	Viela Bio, Inc.	VIELABIO	88420342 05/08/2019	6206619 11/24/2020	Registered
5.	Viela Bio, Inc.	UPLIZNA	88045691 07/20/2018	6164646 09/29/2020	Registered
6.	Viela Bio, Inc.	VIELABIO	88149113 10/10/2018	5691887 03/05/2019	Registered
7.	Viela Bio, Inc.	VIELABIO	88149112 10/10/2018	5691886 03/05/2019	Registered

RECORDATION FORM COVER SHEET TRADEMARKS ONLY

To the Director of the U. S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies):

- 1. Horizon Orphan LLC
- 2. Horizon Therapeutics USA, Inc.
- 3. Viela Bio, Inc.

- Individual(s) Association
 Partnership Limited Partnership
 Corporation- State: _____
 Other 1. LLC-DE; 2. Corp.-DE; 3. Corp.-DE

Citizenship (see guidelines) USA

Additional names of conveying parties attached? Yes No

3. Nature of conveyance/Execution Date(s) :

Execution Date(s) March 15, 2021

- Assignment Merger
 Security Agreement Change of Name
 Other _____

2. Name and address of receiving party(ies)

Additional names, addresses, or citizenship attached? Yes No

Name: Citibank, N.A.

Street Address: 388 Greenwich Street

City: New York

State: NY

Country: USA Zip: 10013

Individual(s) Citizenship _____

Association Citizenship USA

Partnership Citizenship _____

Limited Partnership Citizenship _____

Corporation Citizenship _____

Other _____ Citizenship _____

If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No
(Designations must be a separate document from assignment)

4. Application number(s) or registration number(s) and identification or description of the Trademark.

A. Trademark Application No.(s) Text
See Schedule A

B. Trademark Registration No.(s)
See Schedule A

Additional sheet(s) attached? Yes No

C. Identification or Description of Trademark(s) (and Filing Date if Application or Registration Number is unknown):

5. Name & address of party to whom correspondence concerning document should be mailed:

Name: Elaine Carrera, Senior Paralegal

Internal Address: _____

Street Address: c/o Cahill Gordon & Reindel LLP,
32 Old Slip

City: New York

State: NY Zip: 10005

Phone Number: (212) 701-3365

Docket Number: _____

Email Address: ecarrera@cahill.com

6. Total number of applications and registrations involved: 7

7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$ _____

Authorized to be charged to deposit account

Enclosed

8. Payment information:

Deposit Account Number _____

Authorized User Name _____

9. Signature: *Elaine Carrera*
Signature

March 15, 2021
Date

Elaine Carrera
Name of Person Signing

Total number of pages including cover sheet, attachments, and document. 6

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to: Mail Stop Assignment Recordation Branch, Director of the USPTO, P.O. Box 1460, Alexandria, VA 22313-1450